{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":".090","upperLimit":".437","value":".231"}]}],"title":"Overall Response Rate"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":".116","upperLimit":".478","value":".269"}]}],"title":"Clinical Benefit Rate"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":".804","upperLimit":".999","value":".962"}]}],"title":"Disease Control Rate"}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive pomalidomide PO QD on days 1-21 and dexamethasone PO QD on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving disease progression may cross over to Arm II.","id":"OG000","title":"Arm I(Pomalidomide, Dexamethasone)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Response Rates (Overall Response Rate (ORR), Clinical Benefit Rate (CBR), Disease Control Rate (DCR) for All Patients on the Pomalidomide/Dexamethasone Arm at the Time of Cross-over to Pomalidomide/Dexamethasone/Ixazomib (Phase II)","type":"SECONDARY","unitOfMeasure":"proportion of partcipants"}